Full Press Release Details
SAN DIEGO , Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov. 28, 2017 , in New York City . Timothy P. Coughlin , Vice President Finance of Neurocrine Biosciences, will present at the conference.
The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com . A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month .
About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA ® (valbenazine) capsules in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.